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Summary 
Background: In people, hypercortisolism (HC) causes systemic hypertension, specific 
secondary cardiac changes and increased morbidity and mortality. In dogs, HC is considered 
an important cause of systemic and possibly pulmonary hypertension (PH) potentially causing 
or complicating cardiac disease. Secondary cardiac changes have not been described. 
Objectives: To induce systemic arterial hypertension by iatrogenic HC (IHC), to evaluate the 
development of PH, and to study the effects on cardiac hypertrophy and function. 
Materials and methods: 6 Beagles received oral hydrocortisone and 6 Beagles placebo for 84 
days. Left ventricular (LV) mass and morphology, LV and right ventricular (RV) systolic and 
diastolic function, and evidence of PH were assessed by repeated two-dimensional, Motion 
Mode, Flow and Tissue Doppler echocardiography.  
Results: IHC led to a significant but only mild increase in systemic blood pressure (BP). LV 
hypertrophy and asymmetry could not be observed, and calculated LV mass index and 
eccentricity indices did not change significantly. Relevant significant changes in LV and RV 
systolic and diastolic function could not be observed with routine Teichholz and flow Doppler 
parameters and the newer Tei and modified Tei indices. Direct or indirect evidence of PH was 
not detectable. 
Conclusions: IHC leads to a significant but only mild increase in BP, but not to relevant 
changes in LV and RV dimension or function and PH, detectable by echocardiography.  
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INTRODUCTION 
Hypercortisolism (HC) has important effects on the cardiovascular system in people causing 
systemic arterial hypertension, atherosclerosis and an increased thromboembolic risk.1,2,3 The 
prevalence of hypertension in spontaneous hyperadrenocorticism (HAC) has been reported to 
range between 55 and 80%.4,5,6 In iatrogenic hypercortisolism (IHC), the prevalence of 
hypertension is much lower, with about 20% of patients who receive 
glucocorticoids chronically for various diseases being hypertensive; in these cases 
hypertension is dose-dependent.7,8 Patients with HC have a 4 to 5 times higher mortality 
mainly due to cardiovascular disease, typical causes of death being congestive heart failure, 
cardiac and cerebral stroke.5,9,10   
The exact mechanism of the hypertension is not clearly determined. Considered mechanism 
are abnormal renal vascular resistance and increased pressor responsiveness, decreased nitric 
oxide (NO) activity, and absence or lack of the enzyme 11β-hydroxysteroid dehydrogenase 
type 2 leading  to  increased local exposure to excess cortisol.2,11 Furthermore erythropoietin 
is discussed to change regional resistance in blood vessels by causing relative NO resistance.2  
Little is known about the cardiovascular effects of HC in small animals. In dogs, HAC is 
considered an important cause of hypertension.13  that may contribute to the development of 
left sided heart failure in association with underlying cardiac disease. Hypertension also has 
been recognized in close relationship to acute death in dogs shortly after treatment for HAC 
had been initiated.a Also, severe pulmonary arterial hypertension (PH) causing right sided 
heart failure has been observed in association with HAC.14 In cats, the development of 
reversible congestive heart failure mimicking hypertrophic cardiomyopathy has been 
observed in association with glucocorticoid applicationb, but this could not be reproduced 
experimentally.15  
Secondary morphologic cardiac changes induced by the increased afterload of hypertension 
have been described in people and cats, and include left ventricular (LV) hypertrophy and 
abnormalities in systolic and diastolic function.16,17 Interestingly, in cortisol-induced 
hypertension in people secondary morphologic cardiac changes do not simply reflect the 
degree of increased afterload. LV hypertrophy disproportionate to the degree of hypertension, 
asymmetrical septal hypertrophy, and changing eccentricity indicate cortisol by itself to 
induce LV remodeling.18,19,20,21,22  
In dogs, effects of HC or hypertension on LV and RV morphology and function have not been 
reported. Thus, the aims of this study were to induce IHC and associated hypertension, in 
order to evaluate echocardiographically the secondary effects on LV morphology and 
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function, to evaluate for the development of PH and its effects on right ventricular (RV) 
function. Besides routine M-Mode and Doppler parameters of ventricular dimension and 
function, LV mass and eccentricity indices, LV and RV Tei and modified Tei indices were 
calculated and references values are provided.  
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MATERIALS AND METHODS  
This randomized, placebo-controlled study was approved by the Cantonal Veterinary Office 
(Zurich, Canton of Zurich, Switzerland). 
 
Dogs 
Twelve 3.5-year old laboratory Beagles, 6 intact males and 6 intact females, with a body 
weight ranging from 9.6-14.8 kg (median 12.9 kg) were studied. Dogs were determined to be 
healthy on the basis of physical examination, complete blood count, serum biochemistry 
profile, urinalysis and indirect systemic arterial blood pressure (BP) measurement.  
 
Study Design 
In order to mimic the natural disease as closely as possible the natural glucocorticoid 
hydrocortisone was used to induce HC. The dosage was chosen extrapolating from previous 
studies inducing IHC in dogs.23,24  Dogs were randomly allocated to two groups of 6 dogs. 
Dogs in the treatment group received hydrocortisonec  at a median dose of 8.5 mg/kg (range 
of 7.5-9.6 mg/kg) per os q12h for 84 days (IHC group), while dogs in the control group 
received a placebo gelatin capsule per os q12h. BP measurements were performed before 
(d0), on day (d) 1, d5 d28, d56, d84 of treatment and on post drug withdrawal days d1p, d5p, 
d28p, d56p and d84p. Echocardiographic examinations were performed on d0, d28, d56, d84 
and on d28p, d56p and d84p.  
 
Blood pressure measurement 
Before the beginning of the study, dogs were acclimated to the BP measurement procedure on 
12 different days, to minimize excitement and anxiety during the study.25 Systolic (SAP), 
diastolic (DAP) and mean (MAP) arterial pressure were measured using an indirect 
oscillometric device.d An inflatable cuff of approximately 40% of the tail circumference was 
placed directly around the base of the tail without clipping hair.26 Before recording BP, dogs 
were placed in left lateral recumbency and allowed to acclimate to the surroundings for at 
least 10 minutes and the first BP readings were discarded. For data analysis the arithmetic 
mean of 10 measurements was used. 
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Echocardiographic measurements 
Images for Two-dimensional (2D), Motion (M)-mode, Color, Pulse wave (PW), Continuous 
wave (CW) and PW Tissue Doppler (TDI) echocardiography were performed by one operator 
blinded to the treatment with an Acuson Sequoia 512. Echocardiographic images were 
obtained from the dogs placed in right and left lateral recumbency on a cardiac table 
according to published standards.27 2-D and M-mode echocardiographic images were 
obtained using a 7 MHz transducer, and Doppler images were obtained using a 3.5 MHz 
transducer. All data were stored digitally and measured offline. 
 
Echocardiographic parameters 
Quantitative 2-D parameters and views included LV systolic and diastolic eccentricity indices, 
shortening fraction (%FS) and LV mass index. Systolic and diastolic eccentricity indices 
(LVEID, LVEIS) were calculated by dividing the LV septo-lateral diameter by the 
perpendicular diameter as described.28 Briefly, in right parasternal short axis the maximum 
diastolic septo-lateral diameter was obtained from between the papillary muscles to the 
septum on a frozen image just below the mitral valve level at the beginning of the QRS 
complex using the trailing edge to leading edge method. The maximum cranio-caudal 
diameter was measured on the same image on the perpendicular axis (Fig. 1).  
 
Fig. 1. Two-dimensional echocardiographic image to obtain LV perpendicular and 
septo-lateral diameters to calculate LV diastolic eccentricity index. 
 
 
 
 
 
 
 
 
 
 
 
 
For calculating the LV 
eccentricity index, the 
septo-lateral diameter 
(narrow arrow) is 
divided by the 
perpendicular diameter 
(fat arrow). 
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The minimum systolic diameters were analogously obtained at the moment of maximal 
systolic contraction. These diameters were also used to calculate 2D %FS. For each 
parameter, the mean of 5 beats was calculated.  
LV mass  was calculated by the area length method and the formula LV mass = 1.05 {[5/6 A1 
(a+d+t)] – [5/6 A2 (a+d)]}, and indexed to the body surface area. For the calculations, LV area 
was obtained at end diastole along the outer surface of the left ventricle and right sided 
surface of the septum (A1) and along the subendocardial surface excluding the papillary 
muscles (A2) just below the mitral valve in right parasternal short axis, maximum LV length 
was obtained at end diastole form the endocardial apex to the anterior mitral leaflet insertion 
in right parasternal long axis.29,30  The papillary muscles were excluded because they 
contribute only little to the total wall volume or mass, and inclusion would lead to 
overestimation.16  For each parameter, the mean of 5 measurements was calculated. Routine 
M-Mode Teichholz parameters were obtained from the right parasternal short axis view. 
Systolic time intervals (STIs, pre-ejection period PEP, ejection time ET and PEP/ET) were 
obtained from the right parasternal LV outflow tract view.31  
PW and CW Doppler images from all valves were obtained from right parasternal short axis, 
left caudal and left cranial views, using Color Doppler guidance and modifying the position of 
the probe to obtain optimal alignment with flow. Parameters measured at the semilunar valves 
were peak velocities (Vmax), velocity time integrals (VTI) and STIs including PEP, ET, 
acceleration (AT) and deceleration time (DT). Parameters measured at the atrioventricular 
(AV) valves were peak E and A velocities, E/A ratio, E wave deceleration time (DTE) and the 
duration of the A wave (TA). LV and RV Tei indices of global myocardial performance were 
calculated by the formula (a-b)/b where a is the time interval between the end of the A-wave 
and the onset of the next E-wave and b is the ET32, 33 (Fig. 2). AV-valve inflow and ET time 
were not obtained from the same cardiac cycle (Fig. 3), and ET for RV Tei index was 
measured from the right parasternal short axis as well as the left cranial view.34,35 For Tei 
index calculations, the mean of 10 measurements was obtained.  
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Fig. 2. Schematic of Doppler Intervals to calculate the LV Tei-index (index myocardial 
performance, IMP)* 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Echocardiographic images to demonstrate the measurements for calculating the 
RV Tei-index 
 
 
 
 
 
 
 
The left image is obtained from the left parasternal apical 4-chamber view. The sample 
volume is placed at the tip of the tricuspid valve to obtain right ventricular inflow. The time 
period between the two white lines represents the end of atrial filling (end of A-wave) till 
the beginning of the fast filling phase (beginning of E-wave).  
The right image is obtained from the right parasternal short axis view. The sample volume is 
placed at the tip of the pulmonic valve to obtain right ventricular outflow. The time period 
between the two white lines represents the right ventricular ejection time.  
a = Interval between cessation and onset of 
mitral inflow 
b = ejection time of LV outflow 
 
 
Other intervals depicted in schematic are 
ICT = isovolumic contraction time  
IRT = isovolumic relaxation time 
 
 
*aus Tei C. et al., J Am Soc Echo 1997, 169-178. 
 
 
 10 
PW TDI for calculating the modified Tei indices were obtained from the right parasternal 
short axis view between the papillary muscles for the LV free wall motion, from the left 
caudal view below the mitral valve anulus for the interventricular septal motion and from the 
left cranial view below the tricuspid valve anulus for the RV free wall motion (Fig. 4). The 
sample volume was put at 2 mm, high velocity low intensity signals were filtered out, and the 
resulting velocities were recorded at a sweep speed of 100 mm/s. The modified Tei index was 
calculated by the formula (am-bm)/bm where am  is the time interval between the end of the a-
wave and the onset of the next e-wave and bm is the ET.36,37  
 
Fig. 4. Echocardiographic image to obtain measurements for calculating the RV 
modified Tei-index 
 
 
 
 
 
 
 
 
 
Statistical analysis 
Results were analyzed using nonparametric statistical methodse,f and are reported as median 
and ranges. Differences within groups over time were tested by the Friedman's repeated 
measures test followed by Dunn's post-tests. Differences between groups were tested using 
the Mann-Whitney U test and considered significant at p ≤ 0.05. Intraoperator interday 
variability as index of reproducibility was assessed by calculating the coefficient of variation 
(CV) using the data in the control dogs at each examination time.38  
 
The image is obtained from the left 
parasternal apical 4-chamber view. The 
sample volume is placed at the anulus of 
the tricuspid valve on the right 
ventricular free wall to obtain right 
ventricular myocardial motion. The time 
period between the upper two white lines 
represents the right ventricular ejection 
time. The time period between the lower 
two white lines represents the sum of 
isovolumic contraction time + ejection 
time + isovolumic relaxation time.  
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RESULTS 
 
Induction of hypercortisolism 
All dogs in the I-HC group developed typical clinical signs of cortisol excess including  
polyuria, polydipsia, no regrowth of clipped hair within 1 month, and thinning of the ventral 
abdominal skin with prominent subcutaneous veins. They also developed typical laboratory 
abnormalities, i.e. stress leukogramm, increased alkaline phosphatase activity, isosthenuria. 
Finally, plasma cortisol concentrations were significantly higher in dogs in the IHC group. 
 
Blood Pressure  
Systolic BP significantly increased from a baseline of 123mmHg (114-136 mmHg) peaking at 
143 mmHg (128-148 mmHg, p < 0.01) on d28. The highest systolic BP obtained in any 
individual IHC dog was 148 mmHg on d28. Diastolic BP increased from 69 mmHg (53-78 
mmHg) peaking at 82 mmHg (74-82 mmHg, p < 0.05) on d56. The highest diastolic BP 
obtained in any individual IHC dog was 90 mmHg on d28. Mean BP increased from 90 
mmHg (81 – 101 mmHg) peaking at 103 mmHg (96 – 105 mmHg, p < 0.05) on d56. On d84 
diastolic and mean but not systolic BP were still significantly higher than at baseline (Fig. 5). 
 
LV morphology and mass 
No development of left ventricular hypertrophy or asymmetry under hydrocortisone treatment 
was evident with 2D or M-Mode parameters. During the 6-month study period in IHC dogs, 
LV eccentricity indices in diastole varied between 1.12 (1.05-1.24) and 1.24 (1.19-1.34 ), in 
systole between 0.98 (0.80-1.01) and 1.04 (0.98-1.08) without significant change or even a 
pattern. LV mass index did not increase, but rather decreased at 2 and 3 months post initiating 
hydrocortisone treatment, however, changes were not change (Fig. 6). There was not either 
evidence of LV volume overload as assessed by LV diastolic diameter, measured in 2D septo-
laterally and perpendicularly, measured in M-Mode, and assessed by LV diastolic area. The 
2D septo-lateral LV diameter only poorly correlated with the routine M-Mode LV diameter. 
Selective results of 2D parameters of all 12 dogs at baseline and the CVs are shown in table 1. 
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Fig. 5. Systolic systemic arterial blood pressure in six healthy control beagles (left) and  
six Beagles with iatrogenic hypercortisolism (right)* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Schellenberg S, Mettler M, Gentilini F, Portmann R, Glaus TM, Reusch CE. The effects 
of hydrocortisone on systemic arterial blood pressure and urinary protein excretion in dogs. 
J Vet Intern Med 2008;22:273-81. 
 
d0 = baseline, d1-d56 = hydrocortisone respectively placebo administration,  
d1p-d84p = follow-up examinations after hydrocortisone respectively placebo withdrawal. 
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Fig. 6. LV-mass index in 6 Beagles with iatrogenic hypercortisolism. 
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There was no increase in LV mass index during hydrocortisone treatment. Rather, LV 
mass index decreased during hydrocortisone therapy, however, changes were not 
significant.  
 
x-axis represents measurements time points at: 
1 = one month before starting oral hydrocortisone application 
2 = one day before starting oral hydrocortisone application 
3, 4, 5 = 28 days, 56 days and 84 days after starting oral hydrocortisone application 
6, 7, 8 = 28 days, 56 days and 84 days after discontinuing oral hydrocortisone 
application. 
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Table 1: Selective quantitative 2-dimensional LV parameters in 12 healthy Beagles 
  
Parameter Median (range) Unit CV* (median and range) 
EccD 1-15 (1.10-1.25) - 3.80 (2.87-6.64) 
EccS 1.00 (0.84-1.08) - 6.46 (4.63-8.62) 
%FSsl 0.34 (0.20-0.40) - 11.17 (8.77-16.20) 
%FScc 0.41 (0.33-0.50) - 6.63 (3.65-12.38) 
LVMI 115.4 (100.0-138.4) g/m2 6.85 (4.18-10.47) 
 
 
 
 
 
 
 
 
 
LV function 
With 2D, routine Teichholz and M-Mode STI parameters neither significant functional 
changes nor any tendencies were discernible. Concerning the not routinely calculated 
parameters, in IHC dogs 2D %FS septolateral varied between 0.29 (0.19-0.40) and 0.36 (0.20-
0.39), 2D %FS craniocaudal varied between 0.36 (0.34-0.52) and 0.45 (0.37-0.52), and both 
only poorly correlated with routine M-Mode %FS. 
Flow Doppler evaluation at the mitral inflow as well as aortic outflow did not reveal 
differences induced by hydrocortisone, with few exceptions. Vmax of the A-wave 
significantly increased from 0.45 m/s (0.36-0.50 m/s, d0) to 0.58 m/s (0.47-0.61 m/s, d56, 
p=0.017) and decreased again to 0.42 m/s (0.39-0.58 m/s, d84p, p=0.095), without associated 
significant change of the E/A ratio. VmaxAo increased steadily and significantly from 1.3 m/s 
(1.1-1.3 m/s, d0) to 1.4 m/s (1.3-1.8 m/s, d56, p= 0.026) and decreased again to 1.2 m/s (1.1-
1.4 m/s, d56p). LVAT decreased  from 41.2 ms (36.0-51.7 ms, d0) to 38.6 ms (34.0-48.6 ms, 
d56, p=0.24) and increased again to 43.4 ms (35.0-51.7 ms, d84p), however, changes were not 
significant. LVET steadily decreased from 178 ms (161-193 ms, d0) to 162 ms (137-178 ms, 
d 84, p = 0.041). LVPEP decreased from 53 ms (48-62 ms, d0) to 48 ms (44-60, d 84, p = 
0.39.) After withdrawal of hydrocortisone, both LVET and LVPEP again increased.  
* Coefficient of variation, calculated on results of 7 measurements at monthly intervals 
in 6 healthy Beagles 
 
EccD, EccS = LV eccentricity index in diastole, systole;  
%FSsl, %FScc = 2D short axis LV shortening fraction, septolateral, craniocaudal; 
LVMI = LV mass index, calculated by the area-length method 
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The LV Tei-index fluctuated between 0.37 (0.33-0.68) and 0.52 (0.45-0.65), the modified LV 
Tei-indices obtained at the left ventricular free wall (Fig. 7) varied between 0.68 (0.65-0.92) 
and 0.81 (0.69-1.17), at the interventricular septum between 0.70 (0.65-0.85) and 0.81 (0.64-
1.08), all without any significant change or even tendency during hydrocortisone application.  
The CV for the reproducibility of the LV Tei-index was 18.4%, and of the modified Tei-
indices were 10.6 and 7.4%, respectively. The results of LV flow and tissue Doppler 
parameters of all 12 dogs at baseline, and the CVs are summarized in table 2. 
 
 
Fig. 7. LV modified Tei-index in six healthy control beagles (left) and  six Beagles with 
iatrogenic hypercortisolism (right) 
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d0 = baseline, d1-d56 = hydrocortisone respectively placebo administration, 
d1p-d84p = follow-up examinations after hydrocortisone respectively placebo withdrawal. 
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Table 2: LV Flow and Tissue Doppler parameters in 12 healthy Beagles 
 
Parameter Median (range) Unit CV* (median and range) 
Vmax Ao 1.27 (1.04-1.35) ms 8.2 (5.9-9-9) 
VTI Ao 0.12 (0.10-0.15) m 6.0 (3.8-11.1) 
PEP 52.0 (48.0-62.0) ms 9.8 (7.6-12.5) 
ET 176.7 (160.6-193.2) m/s 4.2 (3.9-7.6) 
PEP/ET 0.30 (0.26-0.33) - 11.6 (8.8-15.5) 
AT 41.6 (36.0-53.8) ms 9.7 (6.4-13.4) 
AT/ET 0.24 (0.21-0.28) - 8.9 (5.7-10.7) 
MVE 0.66 (0.53-0.82) m/s 7.1 (5.4-11.1) 
MVA 0.47 (0.36-0.66) m/s 15.5 (9.8-20.9) 
MVE/A 1.34 (0.97-1.85) - 15.1 (10.4-15.6) 
MVDTE 63.0 (48.2-71.8) ms 16.4 (11.0-25.2) 
MVTA 78.0 (64.4-84.0) ms 9.6 (8.1-17.7) 
Tei 0.51 (0.38-0.60) - 18.8 (9.8-21.5) 
TDI Tei LVW 0.80 (0.64-1.17) - 10.6 (7.6-13.0) 
TDI Tei IVS 0.78 (0.65-0.91) - 11.0 (6.2-12.7) 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Coefficient of variation, calculated on results of 7 measurements at monthly intervals in 6 
healthy Beagles 
 
Vmax, VTI = blood flow peak velocity, velocity time integral across aortic valve; 
PEP = pre-ejection period; ET = ejection time; PEP/ET = pre-ejection to ejection time ratio; 
AT = acceleration time; AT/ET = acceleration time to ejection time ratio;  
MVE, MVA = mitral valve peak E and A velocity; MVE/A = mitral valve peak E to A ratio; 
MVDTE = mitral valve E wave deceleration time; MVTA = mitral valve A wave duration; 
Tei = LV Tei index; TDI Tei LVW = LV modified Tei index of the LV free wall;  
TDI Tei IVS = LV modified Tei index of the interventricular septum. 
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Right ventricular size and function and evidence of pulmonary 
hypertension 
Right ventricular dimensions (RVWd and RVDd) obtained by M-Mode did not change during 
hydrocortisone treatment. These 2 parameters had poor reproducibility with CVs above 20%. 
Flow Doppler examination at the pulmonic outflow as well as the tricuspid inflow revealed 
only a few differences induced by hydrocortisone. RVET obtained from the right short axis 
steadily decreased from 193 ms (178-218 ms, d0) to 177 ms (153-203 ms, d84, p = 0.093), 
RVET from the left cranial view decreased from 197 ms (179-201 ms, d0) to 186 ms (164-
195 ms, d84, p = 0.065), and both increased again after hydrocortisone withdrawal. AT/ET 
increased from 0.36 (0.32-0.42, d0) to 0.39 (0.38-0.47, d84, p = 0.180) and decreased again 
after hydrocortisone withdrawal. Vmax of the A-wave significantly increased from 0.37 m/s 
(0.31-0.45 m/s, d0) to 0.46 m/s (0.42-0.60 m/s, d56, p=0.009), with associated significant 
decrease of the E/A ratio from 1.64 (1.29-1.89, d0) to 1.43 (1.24-1.51, d56, p=0.041). On 
Color Doppler examination, only trivial degrees of pulmonic and tricuspid regurgitation were 
detectable, insufficient to accurately calculate PA-to-RV- or RV-to-RA-gradients. 
The RV Tei-index with ET obtained from the right side varied between 0.11 (0.08-0.27) and 
0.22 (0.10-0.37), with ET obtained from the left side between 0.12 (0.09-0.22)) and 0.22 
(0.01-0.31) without a significant change or a tendency. Reproducibility was poor for both with 
median CVs of 23% and 25 %. The modified RV Tei-index showed a tendency to increase 
from 0.63 (0.57-0.99, d0) to 0.73 (0.66-0.81, d84, p = 0.18, and again decrease after 
hydrocortisone withdrawal (Fig. 8), the median CV was 9.43%. The results of RV flow and 
tissue Doppler parameters of all 12 dogs at baseline, and the CVs calculated in the control 
dogs are summarized in table 3. 
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Fig. 8. RV modified Tei-index in six healthy control beagles (left) and  six Beagles with  
iatrogenic hypercortisolism (right) 
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d0 = baseline, d1-d56 = hydrocortisone respectively placebo administration, 
d1p-d84p = follow-up examinations after hydrocortisone respectively placebo withdrawal. 
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Table 3: RV Flow and Tissue Doppler parameters in 12 healthy Beagles 
 
Parameter Median (range) Unit CV* (median and range) 
Vmax  0.90 (0.64-1.12) m/s 9.97 (3.92-13.38) 
VTI PO 0.11 (0.08-0.13) m 8.77 (7.68-16.05) 
PEP 44.4 (36.4-56.6) ms 8.59 (3.61-10.33) 
ET 192.0 (178.0-218.2) ms 4.01 (3.15-4.79) 
PEP/ET 0.23 (0.19-0.29) - 9.23 (3.84-14.12) 
AT 76.3 (59.2-86.6) ms 8.14 (7.21-11.73) 
AT/ET 0.39 (0.32-0.45) - 8..6 (7.68-10.15) 
DT 117.8 (104.0-138.2) ms 7.04 (5.56-8.92) 
VTI left 0.13 (0.09-0.14) m 9.61 (8.19-13.03) 
Vmax left 1.08 (0.74-1.24) m/s 11.1 (6.31-15.75) 
ET left 196.0 (179.0-201.3) ms 4.1 (2.38-6.09) 
TVE 0.61 (0.47-0.70) m/s 12.47 (8.79-16.00) 
TVA 0.38 (0.31-0.48) m/s 17.19 (13.28-32.96) 
TVE/A 1.55 (1.11-2.09) - 17.52 (14.71-29.77) 
Tei 0.17 (0.07-0.31) - 22.95 (20.29-52.74) 
TDI Tei RVW 0.60 (0.55-0.99) - 9.43 (6.41-13.84) 
 
 
 
 
 
* Coefficient of variation, calculated on results of 7 measurements at monthly intervals in 6 
healthy Beagles 
 
Vmax, VTI = blood flow peak velocity, velocity time integral across pulmonic valve;  
PEP = pre-ejection period; ET = ejection time; PEP/ET = pre-ejection to ejection time ratio;  
AT, DT = acceleration, deceleration time; AT/ET = acceleration time to ejection time ratio;  
VTI left, Vmax left, ET left  = velocity time integral, peak velocity, ejection time obtained 
from the left cranial view;  
TVE, TVA, TVE/A = tricuspid valve peak E and A velocity, and peak E to A ratio; 
Tei = RV Tei index; TDI Tei RVW= RV modified Tei index of the RV free wall 
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DISCUSSION 
Reports from human patients with natural HAC indicate that glucocorticoids have an 
important effect on LV mass and morphology.1,5,10,16,20 Reports from veterinary medicine 
indicate that natural HAC is an important cause of systemic arterial hypertension which then 
would be expected to affect cardiac mass, and extrapolating from human medicine potentially 
also heart shape.10,21 The goals of this study were to induce IHC, to effect secondary systemic 
hypertension, to measure the degree of resulting LV hypertrophy by echocardiography, to 
assess the effects on left ventricular systolic and diastolic function, and finally to assess 
development and degree of HC-induced PH and its effects on RV systolic and diastolic 
function. Besides the attempts to answer these questions using routine quantitative M-Mode 
and flow Doppler echocardiographic parameters, a specific focus in the examinations was 
placed on more sophisticated, not routinely obtained parameters of 2D, M-Mode, flow 
Doppler as well as TDI echocardiography.  
Even though high dose oral hydrocortisone over 3 months, indeed, resulted in clinical HC and 
a significant increase in systemic BP, this increase did not result in any discernible changes in 
LV mass or morphology. Whereas a mild increase in muscle mass may be missed by only 
measuring wall diameters using M-Mode echocardiography, our attempt to detect subtle LV 
hypertrophy by calculating LV mass was not successful, either. Furthermore, we were unable 
to detect the particular pattern of predominant septal hypertrophy described in humans with 
HC, which has been presumed to be a direct effect of excess hydrocortisone on ventricular 
remodeling.38 Finally, the mild increase in BP respectively potential mild increase in 
pulmonary artery pressure did not result in any significant changes in the LV eccentricity 
indices, normal reportedly being around 1.0 in people.28  
Relevant changes in cardiac function secondary to HC and mild BP elevation were not 
discernible, either. AO Vmax significantly increased and LVAT decreased, both changes that 
can be explained with increasing BP. MVA (p=0.017) and MVE/A (p = 0.082) showed a 
significant change or a tendency, respectively, suggesting some diastolic dysfunction. 
However, MVE/A remained above 1 which is considered normal relaxation.39 In addition, 
there was a large overlap of the results, and therefore these statistically significant changes do 
not translate into a clinically relevant change. Newer echocardiographic parameters like STIs, 
Tei-index or modified Tei-index were not more sensitive than routine parameters. Recently, 
TDI measurements of myocardial wall motion velocities were found to be more sensitive for 
detecting early cardiac changes in dogs with Duchenne’s myopathy.40  We did not attempt to 
measure and calculate changes in wall motion velocities, because for one thing meaningful 
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results were not obtainable with our equipment. Furthermore, the clinical value and 
appropriateness of TDI had recently been questioned for reasons like its inability to detect the 
clinically significant peak velocity, its unsatisfactory discriminatory power within the low 
velocity range and its directional bias.41  Nevertheless, it has recently been published that 
reproducible results are obtainable.42  
The primary explanation for our negative echocardiographic findings is the unexpected fact 
that BP elevation was only mild in our dogs. Even though increase in blood pressure was 
consistent and significant, in none of the dogs did BP rise to a level considered to be systemic 
hypertension.  Second, the duration of IHC and associated mild BP elevation was 3 months, 
and natural HAC may be present for months to years before diagnosis. However, it is unlikely 
that longer treatment would have fundamentally changed the BP, because it actually tended to 
again decrease after 2 months of hydrocortisone treatment. Third, duration of 
hypercortisolism rather than duration and degree of hypertension may have been of too short 
duration. Indeed, Fallo et al. suggested long-lasting exposure to increased cortisol, rather than 
hormone or BP levels to be the most relevant determinant of LV concentric remodeling in 
patients with HAC.21 Fourth, our dogs were only 3.5 years old while HAC is more likely a 
disease of older dogs where other factors such as obesity, subnormal thyroid function, latent 
atherosclerosis or diabetes mellitus may influence the BP. Fifth, the dosage chosen is highly 
supraphysiological and did, indeed, result in clinical signs of HC, however, in the natural 
disease there are probably not just 2 daily peaks of only hydrocortisone. Sixth, there may also 
be some kind of adaptation to the exogenous cortisol excess. Therefore, our model of IHC that 
leads to the usual clinical and clinico-pathological changes of HC may only poorly reflect the 
natural disease. Finally, the cardiovascular effects of HC may be overestimated in dogs. 
Systemic hypertension may have been postulated without confirming elevated BP by repeated 
measurements, and adaptation to the measurement procedure itself is of crucial importance.25 
PH is an entity that has been receiving much attention in recent years.43,44,45,46,47,48,49 Several 
causes are established in veterinary medicine, e.g. chronic left ventricular congestive heart 
failure, pulmonary thromboembolism associated with various underlying diseases, and a 
variety of interstitial lung diseases.50  Natural HAC is one risk factor for pulmonary 
thromboembolism in dogs. Furthermore, severe pulmonary hypertension has been described 
in association with HAC, where no pulmonary thromboembolism and no other plausible 
explanation for PH were found on necropsy.14 Therefore, one declared goal of this study was 
to evaluate the effect of IHC on pulmonary artery pressure by echocardiography. The gold 
standard to obtain pulmonary artery pressure is invasive catheterization under anesthesia. 
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Pulmonary artery pressure can also reproducibly and quite exactly be estimated by flow 
Doppler echocardiography, when a measurable jet of tricuspid or pulmonic regurgitation can 
be visualized by color Doppler echocardiography.51 When regurgitation can not be 
documented, indirect parameters for estimating RV pressure are RV STIs, including PEP, RV 
AT and RV AT/ET.46,49 In this study, only trivial regurgitation jets were found, which did not 
allow the calculation of RV pressure and therefore potential changes in RV pressure, i.e. the 
development of PH. However, there were not either relevant changes in indirect parameters of 
PH visible. Even though  Vmax across the pulmonic valve showed a tendency to increase and 
RVET showed a tendency to decrease, both changes associated with developing PH46, these 
changes were not significant. Furthermore, RVAT/ET showed a tendency to increase which is 
opposite to what is expected in developing PH.46,49 Obtaining these Doppler flow parameters 
from the left cranial view including VTI, Vmax and RVET did not yield different results. 
None of the flow profiles across the pulmonic valve showed a shift towards shape with shorter 
AT, higher Vmax, shorter ET, and smaller AT/ET, echocardiographic signs of increasing 
afterload. The observation of decreasing TVE and TV E/A imply some RV diastolic 
dysfunction, but median TV E/A remained above 1 which is considered normal relaxation. 
Finally, only the modified Tei index calculated from the RVW increased and not even 
significantly. Therefore, under the presumption that pulmonary artery pressure did mildly 
increase like systemic BP, these findings would suggest that the modified Tei indices are not 
more sensitive than more established parameters to discern subtle changes in myocardial 
function. 
In conclusion, based on the results of this experimental echocardiographic study, we have to 
dismiss our working hypothesis that IHC in dogs would cause important morphological and 
functional left and right ventricular cardiac changes associated with systemic and pulmonary 
hypertension. Rather, the study allows the only conclusion that 3 months of IHC does not 
measurably affect cardiac dimensions or function.  
Even though our model did not allow us to document the value of echocardiography to detect 
clinically relevant changes in cardiac mass, shape or function,  this study allowed us to 
evaluate the reproducibility of and to provide reference values for several echocardiographic 
parameters that previously have not or only rarely been used in veterinary medicine. The 2D 
eccentricity index, %FS and LV mass index showed good reproducibility with CVs below or 
around 10%. RVWDd and RVDd had the worst CVs among all parameters. Reasons may be 
the difficulty to obtain high quality images at this level in short axis view and the small 
dimensions which tend more to vary. Most flow Doppler parameters had similarly good 
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reproducibility, except mitral and tricuspid valve inflow parameters, as well as LV and RV 
Tei indices with CVs around 15-20%. LV and RV modified Tei indices again had good 
reproducibility with CVs around 10%. The rather poor reproducibility of LV and RV Tei-
indices deserves additional discussion. As a matter of fact, in individual dogs the calculated 
Tei-index gave a negative result. Mathematically simple, a negative result is obtained when 
the sum of the durations of isovolumic contraction time, ET and isovolumic relaxation time is 
shorter than the ET, something that is physiologically impossible. The explanation lies in the 
methodology that these time intervals are not obtained from the same cardiac cycles. Thus, the 
Tei-indices not only were not more sensitive to detect functional cardiac changes but also 
were only poorly reproducible. We therefore question the utility of this parameter for 
assessing global cardiac function. In contrast, the time intervals to calculate the modified Tei-
indices are obtained from the same cardiac cycle and showed good reproducibility.  
In conclusion, high dose oral hydrocortisone did induce HC in healthy Beagles with 
associated mild increase in systolic BP, however, no measurable or relevant effects on cardiac 
morphology, mass or function were detectable.  
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FOOTNOTES 
a Watson P. and Herrtage M., Round Table Discussion on treatment of HC with trilostane, 12. 
ECVIM-CA Conference Munich, 2002. 
b Tobias AH, Proceedings of the 23. ACVIM conference, Baltimore, 2005; pp104-105. 
c Hydrocortisone tablets, Hotz Pharmacy, CH-Kusnacht. 
d SDI, Vet/BP 6000; SDI, Waukesha, WI, USA. 
e SPSS 11.0 for Windows, SPSS Inc., Chicago, IL, USA.  
f GraphPad Prism 4, San Diego, CA, USA.
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